Eltrekibart

厄奇拜单抗

Report date: 2026/04/24 15:37:05

Base Information

Drug NameEltrekibart
Drug Alias NameCXCR1/2L mAb(Eli Lilly and Company)LY-3041658
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionCXC chemokine receptor antagonists
TargetsCXC chemokine receptor
Therapy Area/IndicationsPsoriasisSkin DiseasesColitis, Ulcerative +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[22] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesEli Lilly And Company
Inactive CompaniesN/A
Active IndicationsColitis, UlcerativeHidradenitis Suppurativa
Inactive IndicationsPsoriasisSkin Diseases

Other Information

ATC CodeN/A
Related LinksKEGG